Osteoarthritis (OA) is the most common joint disease due to the increasing life expectancy of the world's population. Every 2nd patient over the age of 50 suffers from knee or hip OA, and this is directly related to the increased burden on healthcare. Accumulated data on the comorbid profile of patients with OA dictate the need to identify disease phenotypes in order to provide personalized care. Individual clinical manifestations of OA also require a differential approach: the pain treatment requires consideration of the patient's psycho-emotional profile and the possibility of involving nociceptive pathways in the process. However, due to the ambiguity of existing clinical guidelines, most experts note a number of difficulties in prescribing treatment for patients with OA.The resolution presents an agreed opinion of experts on the algorithms for managing patients with OA, starting from the primary level, with the gradual involvement of related specialists. Some issues of a personalized approach are considered depending on the presence of comorbid pathology and the severity of individual symptoms of the disease. The prospects of the combined use of pharmacological and non-drug methods of treatment are noted; emphasis was placed on the importance of rehabilitation measures at the first level of medical care, provided to patients with OA, long before the development of structural changes.The proposed algorithms for managing patients can be considered as the basis for future recommendations for managing patients with this pathology.
В статье приводятся данные о распространенности остеоартроза (ОА), частоте коморбидных состояний при этом заболевании. Обсуждаются трудности проведения адекватной и безопасной терапии у таких пациентов. Представлены основные положения клинических рекомендаций по рациональному применению нестероидных противовоспалительных препаратов (НПВП) 2015 г., оценка факторов риска НПВП-ассоциированных осложнений. Обсуждается место медленнодействующих при ОА препаратов (SYSDOA), расхождение взглядов различных национальных и международными сообществ специалистов на их эффективность. Приведены последние рекомендации по ведению больных ОА международного комитета ESCEO 2014 г., в которых подтверждается необходимость назначения SYSАDOA, причем в качестве начального этапа лечения. Приводятся данные о свойствах и функции синовиальной жидкости в норме и при ОА. На основании данных клинических и экспериментальных исследований показано, что, помимо улучшения лубрикационных свойств синовиальной жидкости, экзогенный гиалуронан обладает многими антикатаболическими и анаболическими свойствами, влияет на патогенетически значимые факторы при ОА. Приводятся результаты рандомизированных клинических исследований (РКИ), в которых сравнивали гиалуронаны с различной молекулярной массой. Представлены данные РКИ о клинической эффективности гилана G-F 20 и достоверном уменьшении боли у пациентов с ОА при его использовании. Продемонстированы преимущества в выживаемости обезболивающего эффекта гилана G-F 20 по сравнению с внутрисуставным введение глюкокортикоидов. Приведены имеющиеся данные о структурно-модифицирущем воздействии гилана G-F 20.
Local injection therapy (LIT) is an important component of the complex treatment of musculoskeletal disorders (MSD), which is widely used in real clinical practice. Glucocorticoids, hyaluronic acid drugs (HA), autologous cell drugs, botulinum toxin type A, radioactive isotopes, etc. are used for LIT. LIT makes it possible to achieve a pronounced symptomatic effect, while in some cases, for example, repeated HA treatments in patients with osteoarthritis, the possibility of slowing the progression of the disease and reducing the need for surgical treatment is discussed.The performance of LIT requires special skills and abilities of the physician, careful compliance with the rules of asepsis and antisepsis, and instrumental visualization. LIT can be associated with serious complications and therefore must be performed according to strict indications.The Expert Council was devoted to defining the basic principles of LIT. The indications for the use of certain types of this therapies, the evidence base for its efficacy and safety, the order of application of different drugs, and the need to combine LIT with other drug and non-drug treatments of MSD were reviewed.
16 July 2020 in Meditsinskiy sovet = Medical Council
The article discusses the social significance of osteoarthritis as a widespread disease that develops mainly in older people, which makes it difficult to carry out anti-inflammatory and analgesic therapy due to the frequent combination of osteoarthritis with other diseases at this age, the need to treat comorbid conditions, which is often poorly combined with systemic therapy with non-steroidal anti-inflammatory drugs. It is noted that osteoarthritis not only worsens the quality of life of patients, but also leads to a decrease in the length of their life, which emphasizes the medical and social importance of conducting the safest possible therapy for this disease. Data on the negative impact of the presence of chronic pain on the progression of osteoarthritis are presented. The negative aspects of the use of oral forms of non-steroidal anti-inflammatory drugs are discussed: the development of adverse events primarily from the gastrointestinal tract and cardiovascular system, the negative effect on the synthesis of glycoaminoglycans («chondronegative effect»). Discusses the place of topical forms of NSAIDs in the treatment of patients with osteoarthritis in accordance with the recommendations of the International society for the use of topical forms of NSAIDs in the management of patients with osteoarthritis of large and small joints. Data on transdermal transport of the topical form of diclofenac, a small molecule with lipophilic properties, are presented. Data on the effectiveness of topical forms of diclofenac in comparison with oral forms are presented according to numerous randomized controlled trials, and the comparable effectiveness of both forms of diclofenac is demonstrated, with maximum safety of the topical form. A special structure of Voltaren® Emulgel (Voltaren® Emulgel), combining the properties of a gel and cream, which provides rapid transdermal penetration and longer retention of the active substance in the area of inflammation, is described, as well as a special prolonged form of Voltaren® Emulgel), which creates additional convenience for use.
В статье освещены данные о механизмах действия и эффективности ацеклофенака при хронических воспалительных заболеваниях суставов и позвоночника (ревматоидном артрите, спондилоартритах) и остеоартрите. Показана сопоставимая эффективность ацеклофенака и неселективных нестероидных противовоспалительных препаратов при различных ревматических заболеваниях. На основании результатов рандомизированных контролируемых исследований и метаанализов отмечена высокая безопасность ацеклофенака в отношении желудочно-кишечного тракта, сопоставимая с таковой целекоксиба, в том числе низкий риск развития желудочно-кишечного кровотечения. Поскольку ацеклофенак не оказывает негативного влияния на суставной хрящ и отличается хорошей переносимостью, его можно применять у лиц любого возраста, в том числе длительно, что не отражается на безопасности лечения.
The possibilities of rheumatoid arthritis therapy have been significantly expanded today. In addition to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic agents (BAs), and a targeted synthetic DMARD, a control treatment strategy has been put into practice.The paper demonstrates successes in the early prescription of csDMARD and the implementation of treat-to-target principles – to achieve the goal after 6 months in 50% of patients receiving subcutaneous methotrexate and 45% of those using a Leflunomide generic. During this therapy, there is a lower need for BAs and targeted synthetic DMARDs. The priority problem is to train general practitioners in methods for the early detection of RA and to set up schools for these patients.